Clinical Trial Update: A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating ATN-224 in combination with Bortezomib for multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ATN-224
• Bortezomib (bortezomib)

Snippet

Sponsor: Attenuon | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED